Strategic partnerships Leverage REGENXBIO’s AbbVie collaboration on ABVG-RGX-314 and potential co-development opportunities to cross-sell partnering services, regulatory support, and platform optimization for gene therapies and ophthalmology indications.

Clinical hold risk Monitor RGX-121 FDA clinical hold implications and offer risk-mitigation services, trial design optimization, patient recruitment acceleration, and regulatory submission guidance to maintain momentum and confidence among investors and partners.

Financial runway With substantial funding and a multi-decade cash runway, present financing advisory, milestone-based funding strategies, and CRO/CTO collaborations to support upcoming pivotal trials and potential BLA submissions.

Pipeline leverage Target opportunities around the eye disease program (ABBV-RGX-314) and Duchenne therapy (RGX-202), offering regulatory strategy, biomarker development, and real-world evidence generation to accelerate time-to-market.

Board & governance Capitalize on recent board enhancements to propose governance-focused services, investor communications, ESG reporting, and strategic advisory that align with stakeholder expectations and long-term value creation.